Bausch Health Americas, Inc. Sustainability Profile
Bausch Health Americas, Inc., formerly known as Valeant Pharmaceuticals, is a prominent player in the global healthcare industry, headquartered in the United States. Founded in 1983, the company has evolved significantly, focusing on developing, manufacturing, and marketing a diverse range of pharmaceutical products and medical devices. With a strong presence in North America and expanding operations in Europe and other regions, Bausch Health is dedicated to addressing the needs of patients in areas such as dermatology, ophthalmology, and gastrointestinal health. Its core offerings include innovative therapies and advanced medical technologies that set it apart in a competitive market. Recognised for its commitment to quality and patient care, Bausch Health has achieved notable milestones, solidifying its position as a trusted name in healthcare.
DitchCarbon Score
How does Bausch Health Americas, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bausch Health Americas, Inc.'s score of 40 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bausch Health Americas, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Bausch Health Companies Inc., which may influence its climate commitments and emissions reporting. As part of its corporate family, Bausch Health Americas inherits climate initiatives and targets from Bausch Health Companies Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), although specific reduction targets or achievements have not been disclosed for Bausch Health Americas itself. The absence of detailed emissions data and specific reduction targets suggests that Bausch Health Americas is still in the process of establishing its own climate commitments or may rely on overarching strategies set by its parent company. The company is expected to align with industry standards for climate action, focusing on reducing its carbon footprint in line with global sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Bausch Health Americas, Inc.'s Industry?
How Carbon Intensive is Bausch Health Americas, Inc.'s Location?
Bausch Health Americas, Inc.'s Scope 3 Categories Breakdown
Bausch Health Americas, Inc.'s Scope 3 emissions, which increased by 41% last year and increased by approximately 41% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 21% of total emissions under the GHG Protocol, with "Waste Generated in Operations" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Bausch Health Americas, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bausch Health Americas, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Lumenis Be Ltd.
Sun Pharmaceutical Industries Inc.
SciClone Pharmaceuticals (Holdings) Limited
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.